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Background: Many countries have implemented standardised cancer patient pathways (CPPs) to ensure fast
diagnosis of patients suspected of having cancer. Yet, studies are sparse on the impact of such CPPs, and few have
distinguished between referral routes. For incident cancer patients, we aimed to determine how often GPs
suspected cancer at the time of first presentation of symptoms in general practice and to describe the routes of
referral for further investigation. In addition, we aimed to analyse if the GP’s suspicion of cancer could predict the
choice of referral to a CPP. Finally, we aimed to analyse associations between not only cancer suspicion and time to
cancer diagnosis, but also between choice of referral route and time to cancer diagnosis.
Methods: We conducted a population-based, cross-sectional study of incident cancer patients in Denmark who
had attended general practice prior to their diagnosis of cancer. Data were collected from GP questionnaires and
national registers. We estimated the patients’ chance of being referred to a CPP (prevalence ratio (PR)) using Poisson
regression. Associations between the GP’s symptom interpretation, use of CPP and time to diagnosis were estimated
using quantile regression.
Results: 5,581 questionnaires were returned (response rate: 73.8%). A GP was involved in diagnosing the cancer in
4,101 (73.5%) cases (3,823 cases analysed). In 48.2% of these cases, the GP interpreted the patient’s symptoms as
‘alarm’ symptoms suggestive of cancer. The GP used CPPs in 1,426 (37.3%) cases. Patients, who had symptoms
interpreted as ‘vague’ had a lower chance of being referred to a CPP than when interpreted as ‘alarm’ symptoms
(PR = 0.53 (95%CI: 0.48;0.60)). Patients with ‘vague’ symptoms had a 34 (95% CI: 28;41) days longer median time to
diagnosis than patients with ‘alarm’ symptoms.
Conclusions: GPs suspect cancer more often than they initiate a CPP, and patients were less likely to be referred to a
CPP when their symptoms were not interpreted as alarm symptoms of cancer. The GP’s choice of referral route was a
strong predictor of the duration of the diagnostic interval, but the GP’s symptom interpretation was approximately
twice as strong an indicator of a longer diagnostic interval.
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Standardised cancer patient pathways (CPPs) have been
implemented during the last decade in many countries,
including Denmark, to ensure fast diagnosis of patients
suspected to have cancer. This strategy is intended to
improve patient satisfaction, reduce waiting times and
ensure earlier and faster diagnosis, which should ultim-
ately improve the patient’s prognosis [1-7]. Even though
the contents of the CPPs differ between countries, all
CPPs operate with criteria-based suspicion of cancer and
a guaranteed timeframe.
The UK have introduced two-week wait referrals
(2WW): referrals where the GP suspects cancer and re-
fers the patient as urgent, meaning the patient should be
seen by a specialist within two weeks. To qualify to be
referred as urgent to a 2WW, the patient need to fulfil
the criteria outlined in the NICE guidelines. Previous
studies of the British 2WW referrals have shown that
the general practitioners’ (GPs) use of these referrals was
from one in five to one in three of cancer patients and
that patients not referred urgently had significantly
longer duration of the time to diagnosis [8-13].
In 2007–2009, CPPs were introduced in Denmark for
diagnosis and treatment of suspected cancer as part of
the Danish National Cancer Plan II [2,14]. The Danish
CPPs consisted of guidelines, descriptions of selected
alarm symptoms that may raise cancer suspicion and
well-defined diagnosing schedules from clinical suspi-
cion of cancer until treatment, including specific time
frames; hence the Danish CPPs can be seen as comparable
to the 2WW in the UK. The five Danish regions (i.e. the
hospital owners) were given three months to implement
the guidelines at local level [2]. By spring 2009, CPPs for
32 specific cancers had been developed [2,3].
A key issue for assessment of CPPs is knowledge about
the decisions behind the timing of CPP initiation for a
particular patient. Danish GPs can refer patients to a
CPP when a so-called ‘reasonable suspicion of cancer’ is
raised. This suspicion rests on a combination of evidence
and consensus regarding the possibility of having cancer
when presenting a specific alarm symptom of cancer in
combination with preliminary test results for certain age
groups [2]. Traditionally, ‘alarm’ symptoms and signs of
cancer have been derived from cancer patients symp-
tomatology when the diagnosis has been established, but
many symptoms of cancer are both benign and highly
prevalent in the general population and are often pre-
sented in general practice [15,16]. This may raise con-
cerns as to whether the GP is able to raise a suspicion of
cancer based upon the patient’s symptoms. Furthermore,
it is unknown if the GP may decide to refer to fast-track
diagnosis without ‘alarm’ symptoms or not. Most previ-
ous studies have focused solely on cancer patients with
at least one recorded alarm symptom of cancer [17,18]even though many cancer patients do not present alarm
symptoms [19,20]. Consequently, we need more know-
ledge on how GPs interpret the symptomatology of the
full range of cancer patients and who the GP choses to
refer to a CPP. In addition, we need to know more about
the GP’s handling of cancer suspicion and how this may
influence the time to diagnosis.
For these reasons we hypothesized, that when the GPs’
suspected cancer based upon the patient’s symptoms the
GP would be more likely to use a CPP than when the
GP did not suspect cancer. Furthermore we suspected
that this would influence the duration of the diagnostic
interval by longer diagnostic intervals for those patients,
where the GP did not suspect cancer and also for those
patients not referred to a CPP.
For incident cancer patients, we aimed to determine
how often GPs suspected cancer at the time of first pres-
entation of symptoms in general practice and to describe
the routes of referral for further investigation. In addition,
we aimed to analyse if the GP’s suspicion of cancer could
predict the choice of referral to a CPP. Finally, we aimed
to analyse associations between not only cancer suspicion
and time to cancer diagnosis, but also between choice of
referral route and time to cancer diagnosis.Methods
We conducted a population-based cross-sectional study
of incident cancer patients who attended Danish general
practice prior to the cancer diagnosis.Setting
Denmark has a population of approximately 5.6 million
people and an annual cancer incidence rate of 326 per
100,000 [21]. All citizens in Denmark have free access to
diagnosis and treatment services through the publicly
funded health-care system. Around 98% of all Danish
citizens are listed with a general practice [22], and GPs
initiate diagnostics and act as gatekeepers to specialized
medical care. Danish GPs are legally bound to keep
detailed and contemporaneously updated electronic
medical records of their patients.Study population
We identified all patients aged 18 years or more with an
incident diagnosis of cancer, except for non-melanoma
skin cancer, during four months (1 May to 31 August
2010). The study population was subsequently restricted
to the 73.5% of patients who, according to the GP, had
attended general practice as part of the cancer diagnosis
(Figure 1). The remaining patients were diagnosed through
screening (6.1%), emergency access or as coincidental
findings during diagnostics of other illnesses.
Figure 1 Flowchart showing patient inclusion. Boxes on the left indicate exclusion of patients, while boxes on the right indicate drop-outs.
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Patients were identified using a validated algorithm [23]
that uses data from the Danish National Patient Register
(NPR) of all inpatient and outpatient visits and diagnoses
defined in accordance with the 10th version of the
International Classification of Diseases (ICD-10) [24]. We
verified all diagnoses by linking data to the Danish Cancer
Registry (DCR) [25]. An incident cancer was defined as
having a cancer diagnosis as the primary diagnosis (except
for non-melanoma skin cancer) and no prior history of
cancer recorded in the DCR (previous non-melanoma
skin cancer was allowed).
Data collection
We collected data for each patient by mailing a ques-
tionnaire to the patient’s GP, who was asked to fill out
the questionnaire on the basis of the medical records.
The participating GPs received no remuneration. Non-
responders received a reminder, including a new ques-
tionnaire, after five weeks.
The questionnaire focused on information about the
GP’s interpretation of the symptoms presented by the
patient at the first consultation by asking the GP: ‘How
did you interpret the symptoms?’ The GP was given
three possible categories to answer: alarm symptoms
suggestive of cancer (alarm), symptoms suggestive of any
serious disease (serious), or vague symptoms not directly
suggestive of cancer or other serious disease (vague).Thus, the category of alarm symptoms mirrors the GP’s
suspicion of cancer. However, the GP’s symptom inter-
pretation was subjective and was not based on a pre-
specified list of alarm symptoms.
The questionnaire also requested information about
the choice of referral for further investigation for cancer,
i.e. whether or not a referral was made to a CPP. If no
referral to a CPP had been made, the questionnaire fo-
cused on information about the patient’s referral to spe-
cialist care. This enabled us to classify the GP’s choice of
referral into the following four distinct categories:
Cancer Patient Pathway (CPP), cancer obs. pro. but no
cancer patient pathway, other, or unknown referral.
We defined the diagnostic interval as the time interval
from the date of the patient’s first presentation of
symptoms in primary care until the date of diagnosis in
accordance with the Aarhus Statement [26]. The date of
the patient’s first presentation of symptoms in primary
care was identified by asking the GP the following ques-
tion: “When did the patient first present to your practice
with symptom(s) that you thought were related to the
current cancer diagnosis? (date)” [26]. The date of diag-
nosis was obtained from the DCR; this date corresponds
to the date of the first contact (admission date) with the
hospital department where the cancer diagnosis was first
registered as the primary cause of contact or, if the pa-
tient was diagnosed by a private practicing specialist, this
date corresponds to the date of the clinical diagnosis
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the admission date from the NPR was used.
Possible confounders considered were gender, age,
comorbidity, educational level, disposable income and
region of residence. Patient gender and age were derived
from the patient’s civil registry number (CRN), while
citizenship was derived from the Danish Civil Registra-
tion System [28]. The patient’s complete hospital dis-
charge history (from ten years before the date of the first
consultation with the GP) was used to compute a modi-
fied Charlson Comorbidity Index (CCI) score in accord-
ance with Quan et al. [29]. We grouped CCI into ‘none’
(no recorded disease), ‘moderate’ (index scores of 1 and
2) and ‘high’ (index scores of 3 or more). We used infor-
mation on education from Statistics Denmark [30] to
identify the educational level of all patients in accord-
ance with the International Standard Classification of
Education (ISCED) [31]. We grouped levels of education
into ‘low’ (ISCED levels 1 and 2), ‘medium’ (ISCED levels
3 and 4) and ‘high’ (ISCED levels 5 and 6). Finally, the
disposable OECD household income level [32] was di-
vided into three categories (‘low’, ‘medium’ and ‘high’) on
the basis of data from Statistics Denmark.
More detailed information of identification of patients,
data collection and data items are described elsewhere [33].Ethical approval
The study was approved by the Danish Data Protection
Agency (rec. no. 2009-41-3471). The Danish National
Board of Health (today the Danish Health and Medicines
Authority) gave, according to section 46 of the Danish
Health Act, legal permission to obtain information from
the GPs’ medical records, by questionnaires, without the
patients’ consent (rec. no. 7-604-04-2/195/EHE). According
to Danish law and the Central Denmark Region Committees
on Health Research Ethics, approval by the National
Committee on Health Research Ethics was not required as
no biomedical intervention was performed.Analyses
We present results for the five most frequent cancers in
Denmark (colorectal, lung, malignant melanoma, breast
and prostate [34]) and total. Analyses were performed
on 3,823 cases with complete data (Figure 1). No imput-
ation of missing data was made. Descriptive analyses
were performed using exact non-parametric methods.
We estimated the patients’ likelihood to be referred to
a CPP as a function of GP symptom interpretation by
calculating the prevalence ratios (PRs) using Poisson
regression as we expected the outcome to be frequent
[35]. The analyses were adjusted for patient gender, age,
co-morbidity, educational level, disposable income and
region of residence and for patient clusters at GP level.We estimated the associations between GP symptom
interpretation and diagnostic interval and between use
of CPP and diagnostic interval using the ‘qcount’ pro-
cedure by Miranda [36] for quantile regression analysis
[37] on the smoothed quantiles [38], as we considered
the outcome to be count data (discrete). We adjusted for
patient gender, age, comorbidity, educational level, dis-
posable income and region of residence. Confidence inter-
vals were calculated using standard errors (SEs) estimated
from 1000 repetitions bootstrap.
Statistical significance was set at 0.05 or less, and 95%
confidence intervals are shown when appropriate. Ana-
lyses were done using Stata® v. 13 (StataCorp LP, College
Station, TX, USA).
Results
We identified 7,562 incident cancer patients who fulfilled
the inclusion criteria. A total of 5,581 GP questionnaires
were returned (response rate: 73.8%). The response rate
was higher for female patients, patients diagnosed with
breast cancer and patients with high educational level.
The GPs were not involved in diagnosing the cancer
for 1,480 (26.5%) of the cases; 343 (6.1%) of these were
detected in connection with the national breast cancer
screening programme and 1,130 (20.4%) were detected
otherwise. Patients listed with uninvolved GPs were
more likely to be women, to be 55–64 years of age, to
have higher 1-year survival and to have medium educa-
tional level.
We excluded 278 (6.8%) patients due to missing infor-
mation on three main variables: dates (125 patients
(3.0%)), use of CPP (7 patients (0.2%)) and GP’s symp-
tom interpretation (146 patients (3.6%)) (Figure 1). The
excluded patients were more likely to be diagnosed with
prostate cancer or colorectal cancer, to have moderate
co-morbidity, to be over 75 years of age and to have
distant tumour stage (metastatic cancer).
The analysed patient group thus consisted of 3,823
patients of which 53.3% were males, and 52.5% were
55–74 years of age (Table 1).
Cancer suspicion and use of CPPs
In 48.2% of the cases, the GP interpreted the patient’s
symptom as an ‘alarm’ symptom. This ranged from 31.2%
for lung cancer patients to 80.9% for breast cancer
patients (Table 1). The GP used CPPs in 1,426 (37.3%) of
all cases, ranging from 36.1% for malignant melanoma
patients to 62.5% for breast cancer patients (Table 1). The
GP used CPPs in 52.0% of the cases, who had symptoms
interpreted to be ‘alarm’ symptoms with variation among
the different cancer sites (Table 2).
Referral to a CPP was more likely among male patients
than among female patients (PR = 1.12 (95% CI: 1.00-
1.24)). Referral to a CPP was less likely among patients,
Table 1 Characteristics of included patients for whom the GP was involved in the clinical pathway, shown by cancer
site and total (N = 3,823)
Colorectal Lung Malignant melanoma Breast Prostate Other Total
n(%) n(%) n(%) n(%) n(%) n(%) n(%)
All 612(100) 474(100) 227(100) 518(100) 556(100) 1,436(100) 3,823(100)
Gender
Male 325(53.1) 266(56.1) 100(44.1) 0(0) 556(100) 790(55.0) 2,037(53.3)
Female 287(46.9) 208(43.9) 127(55.9) 518(100) 0(0) 646(45.0) 1,786(46.7)
Age groups (years):
18-44 16(2.6) 3(0.6) 63(27.8) 69(13.3) 0(0) 146(10.2) 297(7.8)
45-54 46(7.5) 42(8.9) 48(21.1) 119(23.0) 20(3.6) 184(12.8) 459(12.0)
55-64 115(18.8) 136(28.7) 43(18.9) 100(19.3) 136(24.5) 325(22.6) 855(22.4)
65-74 219(35.8) 167(35.2) 36(15.9) 91(17.6) 238(42.8) 400(27.9) 1,151(30.1)
> = 75 216(35.3) 126(26.6) 37(16.3) 139(26.8) 162(29.1) 381(26.5) 1,061(27.8)
GP’s symptom interpretation
Alarm 298(48.7) 148(31.2) 121(53.3) 419(80.9) 264(47.5) 592(41.2) 1,842(48.2)
Serious 127(20.8) 162(34.2) 9(4.0) 27(5.2) 59(10.6) 362(25.2) 746(19.5)
Vague 187(30.6) 164(34.6) 97(42.7) 72(13.9) 233(41.9) 482(33.6) 1,235(32.3)
Referral mode
Cancer Patient Pathway (CPP) 222(36.3) 193(40.7) 82(36.1) 324(62.5) 220(39.6) 385(26.8) 1,426(37.3)
Cancer obs – no CPP 108(17.6) 79(16.7) 76(33.5) 92(17.8) 199(35.8) 369(25.7) 923(24.1)
Other 262(42.8) 174(36.7) 61(26.9) 83(16.0) 114(20.5) 613(42.7) 1,307(34.2)
Unknown 20(3.3) 28(5.9) 8(3.5) 19(3.7) 23(4.1) 69(4.8) 167(4.4)
Co-morbidity1
None 453(74.0) 323(68.1) 192(84.6) 406(78.4) 422(75.9) 1,088(75.8) 2,884(75.4)
Moderate 132(21.6) 124(26.2) 33(14.5) 93(18.0) 114(20.5) 286(19.9) 782(20.5)
High 27(4.4) 27(5.7) 2(0.9) 19(3.7) 20(3.6) 62(4.3) 157(4.1)
Missing 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)
Educational level – ISCED2
Low 237(38.7) 211(44.5) 61(26.9) 179(34.6) 182(32.7) 551(38.4) 1,421(37.2)
Medium 230(37.6) 170(35.9) 93(41.0) 202(39.0) 236(42.4) 558(38.9) 1,489(38.9)
High 112(18.3) 73(15.4) 67(29.5) 121(23.4) 126(22.7) 263(18.3) 762(19.9)
Missing 33(5.4) 20(4.2) 6(2.6) 16(3.1) 12(2.2) 64(4.5) 151(3.9)
Disposable income in euro – OECD3
Low 233(38.1) 198(41.8) 50(22.0) 150(29.0) 138(24.8) 494(34.4) 1,263(33.0)
Medium 209(34.2) 161(34.0) 73(32.2) 184(35.5) 194(34.9) 481(33.5) 1,302(34.1)
High 169(27.6) 115(24.3) 103(45.4) 183(35.3) 224(40.3) 460(32.0) 1,254(32.8)
Missing 1(0.2) 0(0) 1(0.4) 1(0.2) 0(0) 1(0.1) 4(0.1)
Region of residence4
North Denmark Region 61(10.0) 43(9.1) 24(10.6) 60(11.6) 81(14.6) 178(12.4) 447(11.7)
Central Denmark Region 141(23.0) 120(25.3) 48(21.1) 129(24.9) 148(26.6) 343(23.9) 929(24.3)
Region of Southern Denmark 139(22.7) 101(21.3) 86(37.9) 128(24.7) 112(20.1) 321(22.4) 887(23.2)
Capital Region of Denmark 142(23.2) 128(27.0) 53(23.3) 109(21.0) 130(23.4) 359(25.0) 921(24.1)
Region Zealand 129(21.1) 82(17.3) 16(7.0) 92(17.8) 85(15.3) 235(16.4) 639(16.7)
1Charlson’s Comorbidity index, 2ISCED = International Standard Classification of Education, 3Disposable income (in thousand of euro according to OECD
classification, 4Region of the patient’s GP as of November 2010.
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Table 2 Number and percentages of Cancer Patient Pathways (CPP) used among patients for whom the GP was
involved in the diagnosis, shown by cancer site and total (N = 1,426)
Colorectal Lung Malignant melanoma Breast Prostate Other Total
n(%) n(%) n(%) n(%) n(%) n(%) n(%)
Total 222(36.3) 193(40.7) 82(36.1) 324(62.5) 220(39.6) 385(26.8) 1,426(37.3)
Gender
Male 130(40.0) 110(41.4) 38(38.0) 0(0) 220(39.6) 230(29.1) 728(35.7)
Female 92(32.1) 83(39.9) 44(34.6) 324(62.5) 0(0) 155(24.0) 698(39.1)
Age groups(years):
18-44 6(37.5) 1(33.3) 22(34.9) 37(53.6) 0(0) 39(26.7) 105(35.4)
45-54 12(26.1) 13(31.0) 15(31.3) 67(56.3) 10(50.0) 53(28.8) 170(37.0)
55-64 50(43.5) 58(42.6) 20(46.5) 62(62.0) 58(42.6) 87(26.8) 335(39.2)
65-74 82(37.4) 74(44.3) 14(38.9) 55(60.4) 104(43.7) 102(25.5) 431(37.4)
> = 75 72(33.3) 47(37.3) 11(29.7) 103(74.1) 48(29.6) 104(27.3) 385(36.3)
GP’s symptom Interpretation
Alarm 163(54.7) 74(50.0) 51(42.1) 305(72.8) 121(45.8) 243(41.0) 957(52.0)
Serious 17(13.4) 52(32.1) 0(0) 5(18.5) 20(33.9) 55(15.2) 149(20.0)
Vague 42(22.5) 67(40.9) 31(32.0) 14(19.4) 79(33.9) 87(18.0) 320(25.9)
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(Table 3). Only the GP’s symptom interpretation remained
statistically significant associated with CPP referral, across
cancer sites, after adjustments, except for malignant
melanoma for which no association was found (Table 3).
Furthermore, even though no overall association between
age and CPP referral was observed, breast cancer patients
aged 45–64 were less likely to be referred to a CPP
(Table 3).Diagnostic interval
The overall median diagnostic interval was 32 days
(interquartile interval (IQI): 14–73) and varied from a
median of 18 (IQI: 8–34) days for breast cancer patients
to a median of 46 (IQI: 21–110) days for prostate cancer
patients (p < 0.001). The diagnostic interval differed
statistically significantly between GP symptom inter-
pretation (p < 0.001) and GP referral modes (p < 0.001)
(Table 4).
The adjusted diagnostic interval was longer when the
GP did not suspect cancer and also when the GP did not
refer to a CPP. Symptoms interpreted as ‘Vague’ displayed
the strongest association with the diagnostic interval,
ranging from an additional 17 (95% CI: 13;21) days at the
25th percentile to an additional 192 (95% CI: -98;483) days
at the 90th percentile compared to patients, who had
symptoms interpreted to be alarm symptoms (Table 5).
The additional diagnostic interval that was associated with
GP’s interpretation of symptoms as ‘vague’ was approxi-
mately twice as long as the additional diagnostic interval
that was associated with non-CPP referral (Table 5).Discussion
The GPs suspected cancer in 48.2% of all cancer patients
and initiated CPP in 37.2% of all cases. Patients had a
lower likelihood to be referred to a CPP if the GP inter-
preted symptoms as ‘vague’ or ‘serious’ compared to
‘alarm’ symptoms. Thus, the GP’s symptom interpret-
ation increased the diagnostic interval for the group
interpreted to have ‘vague’ symptoms (32.7% of all cases)
and the group interpreted to have ‘serious’ symptoms
(19.2% of all cases).
The GP’s symptom interpretation influenced the
diagnostic interval twice as much as the referral mode
chosen by the GP. This indicates that the GP-assessed
severity of symptoms influences the diagnostic interval
more than the GP’s choice of referral mode.Strengths and weaknesses of the study
The size of this study is a major strength as the consider-
able data ensure high statistical precision. Furthermore,
the study population was well-defined and complete with
minimal selection bias as all cases were identified through
the NPR [23,33], wherein 98% of all cancer patients in
Denmark are registered [25]. Yet, we may have missed
some patients due to delay in NPR registrations. However,
this is expected to be negligible as we performed consecu-
tive sampling (including late-registered patients) [23].
The high response rate of 74% further reduces the risk
of selection bias. The small differences in gender for
patients listed with responding and non-responding GPs
should not affect the representativeness of the study as
the cohort resembles patients in the Danish Cancer
Table 3 Patient’s chance of CPP referral initiated by the GP, expressed as adjusted prevalence ratios (PRs) by cancer site and total (N=3,672)
Colorectal Lung Malignant melanoma Breast Prostate Other Total
PRR (95% CI) PRR (95% CI) PRR (95% CI) PRR (95% CI) PRR (95% CI) PRR (95% CI) PRR (95% CI)
Gender
Male 1.08(0.88-1.32) 1.02(0.81-1.27) 1.02(0.72-1.44) n/a 1.00 1.22(1.03-1.44) 1.12(1.00-1.24)
Female 1.00(ref) 1.00(ref) 1.00(ref) 1.00 n/a 1.00(ref) 1.00(ref)
Age groups (years):
18-44 1.67(0.87-3.18) 0.64(0.09-4.32) 1.16(0.60-2.21) 0.86(0.69-1.09) - 0.98(0.71-1.34) 1.04(0.88-1.24)
45-54 1.02(0.63-1.66) 0.72(0.43-1.22) 1.09(0.54-2.19) 0.78(0.64-0.96) 1.70(0.98-2.93) 1.04(0.78-1.39) 0.97(0.84-1.12)
55-64 1.49(1.11-2.00) 0.94(0.68-1.29) 1.69(0.88-3.26) 0.80(0.65-1.00) 1.33(0.96-1.83) 1.05(0.82-1.36) 1.11(0.98-1.26)
65-74 1.18(0.91-1.54) 1.09(0.83-1.42) 1.39(0.72-2.68) 0.88(0.72-1.07) 1.38(1.04-1.84) 0.92(0.72-1.17) 1.06(0.95-1.18)
> = 75 1.00(ref) 1.00(ref) 1.00(ref) 1.00(ref) 1.00(ref) 1.00(ref) 1(ref)
GP’s symptom interpretation
Alarm 1.00(ref) 1.00(ref) 1.00(ref) 1.00(ref) 1.00(ref) 1.00(ref) 1.00(ref)
Serious 0.27(0.17-0.41) 0.64(0.49-0.85) n/a 0.23(0.09-0.56) 0.71(0.47-1.06) 0.34(0.26-0.45) 0.40(0.34-0.48)
Vague 0.40(0.30-0.54) 0.83(0.65-1.05) 0.76(0.52-1.13) 0.27(0.17-0.43) 0.72(0.58-0.90) 0.44(0.35-0.55) 0.53(0.48-0.60)
Adjusted for the patient’s gender, age, co-morbidity, educational background and disposable income, cancer site and patient clusters at GP level.
Estimates marked in bold were statistically significant at minimum level of p < 0.05.

















Table 4 Unadjusted median diagnostic intervals (DIs) with inter-quartile intervals (IQI) displayed for five high
incidence cancer sites and totally (N=3,823)
Colorectal Lung Malignant
melanoma
Breast Prostate Other Total
Median (IQI) Median (IQI) Median (IQI) Median (IQI) Median (IQI) Median (IQI) Median (IQI)
Total 31(14;69) 28(11;67) 28(12;55) 18(8;34) 46(21;110) 40(16;88) 32(14;73)
Gender
Male 28(13;64) 27(9;67) 22(9;53) n/a 46(21;110) 38(15;84) 35(14;81)
Female 35(16;73) 28(13;69) 30(15;56) 18(8;34) n/a 43(17;90) 29(12;63)
Age groups
(years):
18-44 44(31;89) 68(13;96) 31(11;55) 19(11;30) n/a 45(15;116) 30(13;72)
45-54 31(16;61) 18(11;35) 23(12;45) 22(8;36) 47(25;160) 35(16;73) 27(13;54)
55-64 28(11;67) 25(8;44) 24(11;45) 15(6;32) 36(22;105) 38(15;77) 30(13;64)
65-74 30(14;61) 27(9;77) 30(15;56) 21(9;36) 46(22;97) 41(17;90) 35(15;78)
> = 75 34(15;83) 33(14;87) 36(14;68) 14(7;30) 53(17;165) 42(14;94) 34(13;84)
GP’s symptom
Interpretation
Alarm 21(8;41) 15(7;36) 16(6;35) 15(7;28) 36(15;84) 25(10;51) 21(8;42)
Serious 31(16;65) 27(9;65) n/a 29(12;55) 42(25;88) 35(15;74) 33(14;72)




22(8;46) 20(9;46) 15(6;29) 13(5;23) 34(19;75) 29(11;56) 22(8;44)
Cancer obs – no
CPP
29(14;67) 29(12;65) 26(12;45) 28(13;43) 43(21;154) 40(15;79) 34(14;75)
Other 42(21;85) 37(14;89) 56(36;87) 32(18;54) 67(29;165) 51(22;116) 49(21;99)
Unknown 34(10;75) 29(7;69) 20(8;45) 39(17;77) 47(13;505) 36(13;98) 33(12;93)
Estimates marked in bold were statistically significant at minimum level of p < 0.05.
n/a = not applicable.
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to GP non-response may have had longer diagnostic
intervals than the included patients. However, this will
give minimal bias (if any) as we looked at associations
between diagnostic interval and symptom presentation.
Information bias caused by GP recall bias was reduced
as we used the GPs’ contemporaneously updated elec-
tronic medical records. Even so, the retrospective nature
of the questionnaire may imply the risk that some of the
GPs may have misinterpreted the symptoms of a par-
ticular case and hence may have overestimated the pro-
portion of cases with ‘alarm’ symptoms. This would tend
to underestimate the association between the GP’s
assessment of ‘alarm-symptoms’, use of CPPs and the
diagnostic interval. Yet, we believe that this cannot fully
explain the proportion of patients with ‘alarm’ symptoms
found in our study as other studies have found similar
proportions [19,20].
Information bias due to use of ‘date of first contact’ as
‘date of diagnosis’ would tend to underestimate the
length of the diagnostic interval by setting an earlier dateof diagnosis. We consider this to be non-differential as
this is suspected to be the case for all subgroups and
hence will not depend on the GPs symptom interpret-
ation and choice of referral route. Yet, it could be argued
that this information bias would be stronger for patients
who were not referred to a CPP as these have longer
intervals (and thus may have a relatively higher impact
on non-CPP patients). If this is the case, this could lead
to an underestimation of the differences between referral
groups, and the observed differences would thus repre-
sent minimum estimates of the true differences.
Comparison with other findings
Our finding that nearly 50% of cancer patients, who had
symptoms interpreted to be ‘alarm’ symptoms of cancer
prior to a cancer diagnosis represent a slightly higher
number than the previously reported 40% [19,20]. Yet,
this suggests that half of all cancer patients present with-
out an ‘alarm’ symptom of cancer. In combination with
the fact that most symptoms of cancer are highly preva-
lent in general practice [16,19,20], this indicates that a
Table 5 Diagnostic interval in calendar days displayed by GP’s symptom interpretation, referral mode, gender, age
groups and co-morbidity (N=3,672)
Quantile regression results (adjusted)1
25th percentile 50th percentile 75th percentile 90th percentile
n (%) estimate (95% CI) estimate (95% CI) estimate (95% CI) estimate (95% CI)
Gender
Male 1,961 (53.4) −4(−6;-1) −1(−6;3) −6(−21;10) −19(−242;203)
Female 1,711 (46.6) ref. ref. ref. ref.
Age groups (years):
18-44 289 (7.9) −1(−7;4) −1(−9;4) −8(−22;7) −52(−139;35)
45-54 447 (12.2) −2(−6;2) −6(−12;0) −10(−25;5) −37(−276;303)
55-64 835 (22.7) −3(−6;0) −5(−10;1) −11(−29;7) −56(−132;21)
65-74 1,129 (30.7) 0(−2;2) 0(−6;6) −2(−21;17) −30(−107;48)
> = 75 972 (26.5) ref. ref. ref. ref.
GP’s symptom Interpretation
Alarm 1,766 (48.1) ref. ref. ref. ref.
Serious 706 (19.2) 3(0;6) 8(3;13) 24(7;41) 68(−102;237)
Vague 1,200 (32.7) 17(13;21) 34(28;41) 72(38;107) 192(-98;483)
Referral Mode
CPP 1,371 (37.3) ref. ref. ref. ref.
Cancer obs. – no CPP 888 (24.2) 5(1;9) 13(7;19) 32(17;46) 108(−31;248)
Other reasons 1,253 (34.1) 8(4;11) 16(11;22) 34(17;52) 123(86;331)
Unknown 160 (4.4) 3(−7;13) 10(−10;30) 30(1;59) 179(−412;770)
Co-morbidity
None 2,780 (75.7) ref. ref. ref. ref.
Moderate 741 (20.2) −1(−3;1) 2(−2;7) 8(−6;23) 5(−57;66)
High 151 (4.1) −2(−7;4) 1(−9;13) −1(−30;28) −27(−110;55)
Point estimates marked in bold are statistically significant at minimum level of p < 0.05.
1Adjusted for gender, age groups, symptom interpretation, referral mode, cancer site, comorbidity, educational background, disposable income and region of
residence.
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symptoms are presented by the patient.
Our study is the first to document the use of CPP in
primary care for all cancers in Denmark. Our finding
that approximately one-third of all patients are referred
to a CPP is comparable to the findings on the use of
2WW in the UK [8-10,13,39]. The reasons for these
results remain unknown, but it may be suspected that
the criteria behind the ‘reasonable suspicion of cancer’, is
too specific to target the patients’ symptomatology in
general practice, as up to 60% of cancer patients do not
present with alarm symptoms [19,20]. This issue has also
been raised as a concern in the UK [8,13].
To our knowledge, only one study has estimated ad-
justed associations with the diagnostic interval at differ-
ent percentiles, but this study did not adjust for cancer
suspicion nor for the case-mix [40]. Hence, our study is
the first to quantify the associations between cancer
suspicion and diagnostic interval at different percentiles
while also accounting for the case-mix. Even so, ourfinding of an overall (unadjusted) median diagnostic
interval of one month is similar to the findings of other
studies [8,11,12,40-42].
The low use of CPP referrals in combination with a
longer diagnostic interval for patients, whose symptoms
was not interpreted as ‘alarm’ symptoms make us ques-
tion if the CPP (and 2WW) approach to faster diagnosis
is the optimal method to use at the starting point of the
diagnostic trajectory. In fact, we have shown that lack of
cancer suspicion by the GP decreases the likelihood of
CPP referral and influences the diagnostic interval con-
siderably more than the actual use of CPP, in particular
among patients with vague symptoms.
We have also shown that the severity of presented
symptoms was not directly associated with the GP’s use
of a fast-track system. In combination with the English
data that a ‘fast-track’ system may disadvantage the large
group of patients without a warning sign of cancer
[10,13], our finding may be interpreted as a demonstra-
tion of the possible fallacies of the CPP and 2WW
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http://www.biomedcentral.com/1471-2407/14/636referral routes for cancer and why an additional ap-
proach with quick and easy access to all initial investiga-
tions ordered by a GP to qualify the possibility of cancer
may be needed, but further research into the organisa-
tion of rational investigations is highly needed.
Clinical implications
This study underlines the importance for clinicians in
general practice to consider and investigate for cancer
even when the patient does not present well-known
alarm symptoms of cancer. Otherwise, only a proportion
of cancer patients will be provided the faster diagnostic
pathway, leaving approximately half of all cancer patients
to a longer period of uncertainty before diagnosis is
confirmed. This implies that the GPs must have access
to relevant investigations if the aim is to achieve earlier
cancer diagnosis.
Conclusions
GPs suspected cancer more often than they initiated a
CPP, and patients were less likely to be referred to a
CPP if their symptoms were not interpreted to be an
‘alarm’ symptom of cancer. Furthermore, when the pa-
tient’s symptoms were interpreted by the GP as ‘vague’,
this gave rise to a significantly prolonged diagnostic
interval; the impact of the symptom interpretation was
approximately twice that of not using CPP referral
routes. To decrease the time from first symptom presen-
tation until diagnosis for those without alarm symptoms,
GPs may need additional routes other than the fast-track
routes.
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